Highlights
– In SUNMO (phase III, randomized 2:1), mosunetuzumab plus polatuzumab vedotin (Mosun‑Pola) produced a higher overall response rate (70% vs 40%) and longer median progression‑free survival (11.5 vs 3.8 months; HR 0.41) compared with R‑GemOx in transplant‑ineligible relapsed/refractory large B‑cell lymphoma (LBCL).
– Complete response rates were substantially higher with Mosun‑Pola (51% vs 24%).
– Clinically significant cytokine release syndrome (CRS) was uncommon (grade ≥2 CRS and tocilizumab use each <5%), and patient‑reported outcomes favored the Mosun‑Pola arm.
Background: disease burden and unmet need
Relapsed or refractory large B‑cell lymphoma (LBCL) carries a poor prognosis, particularly for patients who are ineligible for curative‑intent therapies such as autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T‑cell therapy because of comorbidity, age, performance status, or logistics. Historically, palliative combination chemotherapy regimens such as rituximab plus gemcitabine and oxaliplatin (R‑GemOx) have been used as salvage options for these patients, but outcomes are modest and toxicities are substantial.
Recent years have seen the development of novel targeted immune therapies for B‑cell malignancies. Mosunetuzumab is a CD20×CD3 T‑cell engaging bispecific antibody that redirects endogenous T cells to kill CD20‑positive B cells. Polatuzumab vedotin is an antibody‑drug conjugate (ADC) targeting CD79b and delivering the microtubule‑disrupting payload monomethyl auristatin E (MMAE). The combination of a T‑cell engager and an ADC aims to leverage complementary mechanisms: T‑cell mediated cytotoxicity and targeted delivery of cytotoxic chemotherapy to B cells. A fixed‑duration, outpatient regimen that is both effective and tolerable would address a major unmet need in transplant‑ineligible r/r LBCL.
Study design
The SUNMO trial is a randomized, phase III study that enrolled patients with relapsed or refractory LBCL considered ineligible for autologous stem‑cell transplant. Patients were randomized 2:1 to receive mosunetuzumab plus polatuzumab vedotin (Mosun‑Pola) or R‑GemOx. The trial used dual primary end points: centrally assessed overall response rate (ORR) and progression‑free survival (PFS). Overall survival (OS) was a key secondary end point. The primary analysis reported here has a median follow‑up of 23.2 months.
A total of 208 patients were randomized: 138 to Mosun‑Pola and 70 to R‑GemOx. Response assessments were performed centrally; safety monitoring included standard adverse event grading and specific surveillance for cytokine release syndrome (CRS) associated with T‑cell engaging therapies.
Key findings
The SUNMO primary analysis demonstrated clinically and statistically significant benefits for the Mosun‑Pola combination versus R‑GemOx across efficacy end points:
- Progression‑free survival: Median PFS was 11.5 months (95% CI, 5.6 to 18) with Mosun‑Pola versus 3.8 months (95% CI, 2.9 to 4.1) with R‑GemOx; hazard ratio (HR) for progression or death was 0.41 (95% CI, 0.3 to 0.6; P < .0001).
- Overall response rate: ORR was 70% with Mosun‑Pola versus 40% with R‑GemOx (P < .0001).
- Complete responses: CR rate was 51% in the Mosun‑Pola arm and 24% in the R‑GemOx arm.
Secondary and safety findings:
- Overall survival was designated a key secondary end point and will be important for long‑term interpretation; OS data were reported as part of the publication and will require longer follow‑up for mature interpretation.
- Safety: clinically significant CRS (grade ≥2) occurred infrequently (reported at <5%); similarly, tocilizumab use for CRS was required in <5% of patients in the Mosun‑Pola arm. These rates indicate a manageable CRS profile when using contemporary mitigation strategies (eg, step‑up dosing and close monitoring).
- Patient‑reported outcomes (PROs) favored Mosun‑Pola relative to R‑GemOx, suggesting better tolerability or symptom control with the novel regimen.
Interpreting efficacy: effect sizes and clinical relevance
The magnitude of benefit reported in SUNMO is notable. A PFS HR of 0.41 represents a 59% reduction in the hazard of progression or death compared with R‑GemOx, and the median PFS advantage (approximately 7.7 months) is clinically meaningful in a population with limited options. The doubling of the CR rate (51% vs 24%) raises the possibility of deeper, potentially durable remissions with Mosun‑Pola, which is particularly relevant for transplant‑ineligible patients whose options for consolidative therapy are constrained.
Response rates and depth of response with Mosun‑Pola are consistent with the expected biologic activity of combining a T‑cell engager and an ADC: mosunetuzumab recruits and activates cytotoxic T cells against CD20+ lymphoma cells, while polatuzumab vedotin delivers targeted cytotoxic payload to CD79b‑expressing B cells. The combination may convert partial responses into complete responses or extend durations of response beyond what is achievable with cytotoxic chemotherapy alone.
Safety and tolerability
Safety is a central concern with immune‑engaging therapies. CRS and immune‑related adverse events are predictable risks with bispecific T‑cell engagers. The reported low rate of grade ≥2 CRS and infrequent requirement for tocilizumab suggest that the Mosun‑Pola regimen can be administered safely in the outpatient setting when appropriate step‑up dosing and monitoring are used. Other adverse events typically associated with polatuzumab vedotin (eg, cytopenias, peripheral neuropathy) and with chemotherapy (eg, transaminase elevations, GI toxicity) should be expected and managed per established guidelines, but the publication emphasizes an overall manageable safety profile.
Expert commentary and study limitations
Strengths of SUNMO include its randomized phase III design, central response assessment, and clinically relevant comparator. The fixed‑duration, largely outpatient nature of the Mosun‑Pola regimen addresses practical barriers for a frail patient population.
Limitations and caveats:
- Population heterogeneity: The enrolled transplant‑ineligible population is likely heterogeneous with respect to age, comorbidity, performance status, number and type of prior therapies, and histologic subtypes (eg, transformed lymphoma). Subgroup analyses (by age, prior lines, cell‑of‑origin, and prior exposure to anti‑CD20 or polatuzumab) will be important to define which patients derive the greatest benefit.
- Long‑term outcomes: While PFS and ORR improvements are compelling, mature overall survival data and longer follow‑up are needed to confirm durable benefit and to better define late toxicities.
- Comparative landscape: The trial compares Mosun‑Pola with R‑GemOx, a commonly used salvage regimen in transplant‑ineligible patients, but not with other contemporary options such as POLA‑BR (polatuzumab‑containing regimens), other bispecific combinations, or CAR T‑cell therapy (which is often not feasible for this population). Cross‑trial comparisons are inherently limited.
- Operational considerations: Successful use of T‑cell engaging antibodies requires clinical infrastructure for early recognition and management of CRS and immune toxicities; access to tocilizumab and experienced nursing and physician support remains essential.
- Cost and access: ADCs and bispecific antibodies are high‑cost therapies, and payer coverage, infusion center capacity, and global access may limit broad implementation despite favorable efficacy.
Clinical implications and practice considerations
For clinicians managing transplant‑ineligible r/r LBCL, SUNMO provides randomized evidence supporting a chemotherapy‑sparing, fixed‑duration outpatient regimen that yields higher response rates and longer PFS than R‑GemOx. Key practice points include the need for structured CRS risk mitigation (step‑up dosing, early monitoring), assessment of comorbidity and immune competence when selecting patients for T‑cell engaging therapy, and discussion with patients about the balance of efficacy, toxicity, logistics, and cost.
Future directions should include subgroup analyses to refine patient selection, combination or sequencing strategies with other immunotherapies, and economic evaluations to inform health‑system adoption.
Conclusion
The SUNMO phase III trial demonstrates that mosunetuzumab plus polatuzumab vedotin provides a clinically meaningful improvement in response rate and progression‑free survival compared with R‑GemOx for transplant‑ineligible relapsed/refractory LBCL, with a manageable safety profile characterized by low rates of clinically significant CRS. These data support Mosun‑Pola as an important new outpatient therapeutic option in a population with substantial unmet need, while underscoring the importance of longer follow‑up, subgroup characterization, and real‑world implementation planning.
Funding and clinicaltrials.gov
Funding sources and the trial registration identifier are reported in the primary publication. See Budde et al., J Clin Oncol. 2025 for full disclosures and the trial registry number.
References
1. Budde LE, Zhang H, Kim WS, et al. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant‑Ineligible Refractory/Relapsed Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. J Clin Oncol. 2025 Oct 2: JCO2501957. doi: 10.1200/JCO-25-01957 . Epub ahead of print. PMID: 41037766 .
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Diffuse Large B‑Cell Lymphoma. Latest version available at www.nccn.org (consult current guideline for recommended therapies and algorithms).